Trials / NCT03011541
Stem Cell Ophthalmology Treatment Study II
Recruiting now N/A Cell therapy
- Sponsor
- MD Stem Cells
- Treatment
- Arm 1
- Gene
- Not stated
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
- Ages
- 18 Years to no upper limit
- Enrollment
- 500 participants
- Started
- 2016-01
- Main results expected
- 2027-07-31
- Results posted
- Not yet
- Record last updated
- 2026-06-29
What the study is testing
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Where it runs
Austria (1)
- MD Stem Cells Kobinia Med, Vienna, Austria (recruiting now)
United Arab Emirates (1)
- The Saudi-German Hospital, Dubai, United Arab Emirates (recruiting now)
United States (2)
- MD Stem Cells, Westport, Connecticut (recruiting now)
- MD Stem Cells, Coral Springs, Florida (recruiting now)